VeroScience

14 articles about VeroScience

• 

  ADA Spotlight: Novo Nordisk, Boehringer Ingelheim, Eli Lilly and More

  6/12/2019

  Almost 15,000 physicians, scientists, health care professionals and industry representatives from around the globe presented research, treatment recommendations and advances toward a diabetes cure at the American Diabetes Association's 79th Scientific Sessions in San Francisco this week.

• VeroScience Presents New Pipeline Data for Metabolic Disease Therapies at 2019 American Diabetes Association Meeting

  6/9/2019

  VeroScience LLC, presented six preclinical studies aimed at new therapeutic approaches for obesity, prediabetes, type 2 diabetes, and Nonalcoholic Fatty Liver Disease/ Nonalcoholic Steatohepatitis (NAFLD/NASH) at the American Diabetes Association's 79th Scientific Sessions in San Francisco, Calif. on June 9, 2019.

• VeroScience Is Pleased To Support Independent Research From The Laboratory Of Dr. Defronzo And Team At UT Health Science Center, San Antonio

  6/13/2016

• VeroScience Continues To Explore Clinical Benefits Of Circadian Neuroendocrine Resetting Therapy With Six Papers Presented At 2016 American Diabetes Association Scientific Sessions June 10-14

  6/13/2016

• Published Review Paper From VeroScience Delineates 50 Years Of Research Linking Circadian Rhythms With Metabolic Disease

  3/16/2016

• VeroScience Release: Two Peer-Reviewed Studies Focusing On Unique Therapeutic Impact Of Veroscience's Cycloset Recently Published In Journal Of Diabetes Research

  6/15/2015

• VeroScience Continues Clinical Evaluation of Bromocriptine-QR (Cycloset) And Neurophysiological Investigations Of Brain Dopamine Regulation Of Metabolism With Eight Papers Presented At The 2015 American Diabetes Association Conference

  6/8/2015

• Santarus Inc. and VeroScience Announce CYCLOSET (bromocriptine mesylate) Data Presentations at the American Diabetes Association Meeting

  6/21/2013

• Santarus Inc. and VeroScience Announce Publication of American Association of Clinical Endocrinologists Expert Panel Recommendations for CYCLOSET® (bromocriptine mesylate) for the Management of Type 2 Diabetes

  3/6/2013

• Santarus Inc. and VeroScience Announce Publication of Positive Data From Pivotal CYCLOSET® (bromocriptine mesylate) Efficacy Study

  1/23/2013

• Santarus Inc. Buys License To Make Diabetes Drug For $5 Mln From S2 Biosciences Inc. And VeroScience

  9/9/2010

• VeroScience Announces FDA Approval of Cycloset for Treatment of Type 2 Diabetes

  5/6/2009

• VeroScience Release: Phase IIIb Clinical Data Validate the Overall and Cardiovascular Safety Profile of Cycloset(TM) in Patients with Type 2 Diabetes

  6/25/2007

• VeroScience Late-Breaking Abstract on Cycloset(TM) (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions

  6/18/2007